Stratégies de traitement en évolution dans le lymphome T périphérique
Résumé
Les lymphomes T périphériques (LTP) sont dérivés des lymphocytes T matures post-thymiques et représentent un groupe de maladies cliniquement et biologiquement hétérogènes. La majorité des LTP ont un pronostic défavorable par rapport à leurs homologues à cellules B agressifs. De plus, en raison de la rareté de la maladie, le traitement optimal demeure inconnu. Une grande proportion de patients présentent de multiples facteurs de risque selon l’International Prognostic Index (IPI) et sont rarement guéris. Les lymphomes anaplasiques à grandes cellules (LAGC) ALK positif font exception, car ce groupe de maladies a un pronostic beaucoup plus favorable. Par contre, les patients atteints de LAGC et de multiples facteurs de risque IPI ont eux aussi un pronostic médiocre.
Références
Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15:1467–1475.
Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008 Sep 1;26(25):4124-30.
Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, et al; International Peripheral T-Cell Lymphoma Project. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011 Mar 24;117(12):3402-8.
Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, et al; International Peripheral T-Cell Lymphoma Project. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008 Jun 15;111(12):5496–504.
Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma. ISRN Hematol. 2011;623924.
Schmitz N, Trümper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, Peter N, Loeffler M, Rosenwald A, Pfreundschuh M. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010 Nov 4;116(18):3418-25.
Horwitz S, O’Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial. Lancet. 2019 Jan 19;393(10168):229-40.
Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas RO, et al. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). J Clin Oncol. 2022 Jan 20;40(3):242-251.
Wulf GG, Altmann B, Ziepert M, D'Amore F, Held G, et al. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial. Leukemia. 2021 Jan;35(1):143-155.
D’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012 Sep 1;30(25):3093-9.
Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, et al; COMPLETE Investigators. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer. 2019 May 1;125(9):1507-1517.
Brink M, Meeuwes FO, van der Poel MWM, Kersten MJ, Wondergem M, et al. Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study. Blood. 2022 Sep 1;140(9):1009-1019.
Ye Y, Ding N, Mi L, Shi Y, Liu W, Song Y, Shu S, Zhu J. Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas. Exp Hematol Oncol. 2021 Feb 5;10(1):9.
Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011 Jun 2;117(22):5827-34.
Coiffier B, Pro B, Prince HM, Foss F, Sokol L, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses. J Hematol Oncol. 2014 Jan 23;7:11.
O’Connor OA, Falchi L, Lue JK, Marchi E, Kinahan C, et al. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: A multicenter phase 1 study. Blood. 2019 Oct 24;134(17):1395-405.
Falchi L, Ma H, Klein S, Lue JK, Montanari F, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: A multicenter phase 2 study. Blood. 2021 Apr 22;137(16):2161-70.
Haverkos BM, Alpdogan O, Baiocchi R, Brammer JE, Feldman TA, et al. Nanatinostat (Nstat) and Valganciclovir (VGCV) in Relapsed/Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphomas: Final Results from the Phase 1b/2 VT3996-201 Study. Blood 2021:138(Suppl 1):623.
O’Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study. J Clin Oncol. 2011 Mar 20;29(9):1182-9.
Amengual JE, Lichtenstein R, Lue J, Sawas A, Deng C, et al. A phase 1 study of romidepsin- and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood. 2018;131(4):397–407.
Brammer JE, Zinzani PL, Zain J, Mead M, Casulo C, et al. Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Results of an Interim Analysis. Blood. 2021;138(Suppl 1):2456.
Horwitz SM, Moskowitz AJ, Mehta-Shah N, Jacobsen ED, Khodadoust MS, et al. The combination of duvelisib and romidepsin (DR) is highly active against relapsed/refractory peripheral T-cell lymphoma with low rates of transaminitis: final results. Hematol Oncol. 2021 Jun 17;39(S2).
Iyer SP, Huen A, Ai WZ, Jagadeesh D, Lechowicz MJ, et al. Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma: Final Results from a Phase I/II Open Label Multi-Center Study. Blood. 2021;138(Suppl 1):1365.
Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, et al. An Open-Label, Single-Arm, Phase 2 Trial of Valemetostat in Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma. Blood. 2022 Sep 23. Epub ahead of print. DOI: https://doi.org/10.1182/blood.2022016862
Ishitsuka K, Izutsu K, Maruyama D, Makita S, Jacobsen ED, et al. First-in-human study of the EZH1 and EZH2 dual inhibitor valemetostat tosylate (ds-3201b) in patients with relapsed or refractory non-hodgkin lymphomas. Hematol Oncol. 2021:39(S2).
Foss FM, Porcu P, Horwitz SM, Izutsu K, Ishitsuka K, Kato K, et al. A global phase 2 study of valemetostat tosylate (Valemetostat) in patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL), including R/R adult T-cell Leukemia/Lymphoma (ATL)-Valentine-PTCL01. Blood. 2021;138(Suppl 1):2533.
Michot JM, Mehta A, Samaniego F, Bachy E, Zinzani PL, Prica A, et al. Preliminary analysis of the phase II study using Tolinapant (ASTX660) monotherapy in 98 peripheral T-cell lymphoma and 51 cutaneous T-cell lymphoma subjects with relapsed refractory disease. HemaSphere. 2022 Jun;6:118-9.
Scarfò I, Frigault MJ, Maus MV. CAR-based approaches to cutaneous T-cell lymphoma. Front Oncol. 2019 Apr 16;9:259.
Iyer SP, Sica RA, Ho PJ, Hu B, Zain J, Prica A, et al. The COBALT-LYM study of CTX130: A phase 1 dose escalation study of CD70-targeted allogenic CRISPR-CAS9-engineered CAR T cells in patients with relapsed/refractory (R/R) T-cell malignancies. HemaSphere. 2022 Jun;6:163-4.
Publié
Comment citer
Numéro
Rubrique
Licence
© Actualité hématologique au Canada 2022
Cette œuvre est sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.
